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Enteric-Coated Fenoprofen in Large-Joint Osteoarthritis* 
Gilbert B. Bluhm, MD,* Harris H. Macllwain, MD,* and Walter W. Offen, PhD§ 
Enteric-coated fenoprofen was compared with standardfenoprofen (Nalfon"", Dista, Indianapolis, IN) 
'in a randomized, double-blind, parallel, three-month trial of 113 outpatients (mean age, 64 years) 
wilh large-joint osteoarthritis. A previous study showed that enteric coating of fenoprofen reduces 
gastrointestinal microbleeding and may offer a safety advantage. Both treatments provided 
slalistically significant improvement in pain measures (tenderness on pressure, pain at rest, pain with 
weight-bearing activity, and pain on passive motion). Adverse experiences were simitar wilh both 
treatments and ofan expected type, severity, and incidence for nonsteroidal anti-inflammatory drugs. 
Enteric-coated fenoprofen was found to be as effective and safe as standard fenoprofen for large-joint 
osteoarthritis. (Henry Ford Hosp MedJ 1988:36:56-60) 
Fenoprofen calcium (Nalfon®. Dista, Indianapolis, IN) is a nonsteroidal anti-inflammatory dmg (NSAID) with anal-
gesic and antipyretic properties. Although its exact mode of 
action is not known, inhibition of prostaglandin synthetase is 
probably involved. As an NSAID, fenoprofen has proven to be 
effective in the treatment of rheumatoid arthritis and large-joint 
osteoarthritis (1). In patients with osteoarthritis, the anti-inflam-
matory and analgesic effects of fenoprofen have been demon-
strated by a reduction in the common measures of disease 
activity. Efficacy and safety of fenoprofen compare favorably 
with those of other agents used to treat osteoarthritis, such as 
aspirin (2-4), indomethacin (5), ibuprofen (6), and sulindac (7). 
However, fenoprofen, like other NSAIDs, is known to produce 
gastrointestinal (GI) irritation, bleeding, and other GI symp-
toms (8). While studies have shown that fenoprofen is safer than 
aspirin and no long-term clinical risks are associated with its use 
for treatment of osteoarthritis (8-10), it is important to minimize 
risks of GI bleeding. 
To protect the mucosal membrane of the stomach from irrita-
tion produced by aspirin and NSAIDs, enteric coatings have 
been developed that do not change the biologic half-life of the 
drug (11). A recent study showed that an enteric-coated form of 
fenoprofen reduced GI microbleeding significantly (12). The 
bioavailability of the two formulations is equal (data on file, 
Lilly Research Laboratories, Indianapolis, IN). 
The purpose of this study was to compare the two formu-
lations to determine whether the enteric-coated form is as 
effective and safe as standard fenoprofen calcium. If so, en-
teric-coated fenoprofen may have fewer adverse Gl effects than 
fenoprofen calcium when used for the long-term treatment of 
large-joint osteoarthritis. 
Materials and Methods 
Patient population 
Male and female ambulatory outpatients, 18 years or older, 
with active osteoarthritis were selected forthe study. All patients 
were taking fenoprofen calcium for their disease condition 
immediately before the trial began. Six independent clinical 
centers participated in the study. 
The presence of osteoarthritis was established by the follow-
ing diagnostic criteria: roentgenological evidence of large-joint 
(hip or knee) osteoarthritis and one or more of the following 
signs and symptoms of osteoarthritis: tenderness on pressure, 
pain on passive motion, pain with weight-bearing activity, 
or pain at rest. The symptomatic knee or hip was the cardinal 
joint evaluated. 
Patients were excluded from the study if they had: 
• evidence of rheumatoid arthritis, lupus erythematosus, 
psoriasis, syphilitic neuropathy, or metabolic bone disease; 
• cardiac, renal, hepatic, gastrointestinal, or other serious dis-
eases that would be exacerbated by the study medications or in-
terfere with study evaluation; 
• hypersensitivity to fenoprofen calcium, aspirin, orother 
drugs; 
• history of alcohol or drug abu.se within one year; 
• clinically significant psychiatric problems; 
• inability to take oral medications. 
Patients with serious di.seases were accepted into the study 
only if the investigator determined that the condition(s) would 
not interfere with the study evaluation. Women of childbearing 
age were included if they were on an effective contraceptive pro-
gram approved by the investigator. The study protocol was 
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approved by the institutional review boards at each of the 
participating centers, and all patients signed an informed con-
sent form. 
Study design 
The study was a randomized, double-blind, parallel ttial con-
ducted at six centers by independent investigators. The study be-
gan with a two-week placebo qualification period during which 
patients were withdrawn from fenoprofen calcium to demon-
strate active osteoarthritis symptoms and to eliminate apparent 
placebo reactors by indicating the need for active medication. 
During this time, patients were allowed to take acetaminophen 
(500 mg) if they required an analgesic to relieve pain. Ifthe 
symptoms of osteoarthritis became unbearable, the placebo pe-
riod was shortened and the patient entered the active treatment 
phase before the two-week period ended. 
After this two-week period, eligible patients were randomly 
allocated to one of two treatment groups: fenoprofen calcium, 
600 mg, or enteric-coated fenoprofen, 600 mg. Patients who en-
tered the active treatment phase received one of the two medica-
tions four times a day for 12 consecutive weeks. No adjustments 
in dosage were permitted, and patients were not allowed to 
switch formulations. Compliance was assessed at each visit by 
counting capsules and by measuring serum fenoprofen calcium 
concentrations. Additional analgesics were not permitted during 
the active treatment period. 
Patients were evaluated by the investigator at four regulariy 
scheduled visits during the three-month period. At each visit, 
the investigator evaluated clinical symptoms of osteoarthritis, 
recorded any adverse events, dispensed the study medication, 
and collected blood or urine samples. At the conclusion of the 
final visit, the investigator prepared a final summary report for 
each patient. 
Measures of efficacy 
Four pain parameters were used to measure the patient's re-
sponse to the study medication: tenderness on pressure and pain 
on passive motion, which were evaluated directiy by the clini-
cian, and pain at rest and pain with weight-bearing activity, 
which were evaluated through interview of the patient. At each 
visit, the investigator rated these parameters on a four-point 
scale: 0 = no pain, I = mild pain, 2 = moderate pain, and 3 = 
severe pain. To minimize variation, the same investigator evalu-
ated the same patient at each visit at approximately the same 
time of day. 
Statistical analysis 
The four efficacy variables were analyzed in two ways. First, 
changes from baseline to endpoint were analyzed by analysis of 
variance (ANOVA) on the ranks of the data. ANOVA was per-
formed twice, first on all data and then on evaluable data alone. 
Baseline was the visit at which the treatment phase began, and 
endpoint was the last visit for which data were collected. 
ANOVA included three independent variables: investigator, 
drugs, and their interaction. In addition, a Wilcoxon rank sum 
test, which does not account for any differences due to investi-
gators, was performed on the four efficacy variables, and a 
Wilcoxon signed rank test was used to analyze the two treatment 
groups individually for any significant changes within the 
group. The second form of analysis used the same statistical 
techniques as the first, but in this case changes from baseline to 
each of the three months of the study were analyzed separately. 
A standard Pearson chi-square test was used to analyze three 
primary reasons for termination from the study: protocol com-
pleted, lack of efficacy, or adverse events. For this study, sta-
tistical significance was defined as P ^ 0.05. All treatment 
comparisons were two-tailed. 
Laboratory studies 
Samples were collected at the beginning of the placebo quali-
fication period and at the end of the last visit for blood chemistry 
profiles, hematological tests, and urinalysis. Compliance blood 
samples were drawn after each ofthe three months of treatment. 
Adverse events 
An adverse event was defined as any undesired occurrence 
during treatment with the medication whether or not it was con-
sidered drug-related. These included any deaths or hospitaliza-
tions, withdrawal from the study due to a serious adverse event, 
change in renal function or proteinuria, melena or Gl perfora-
tion, obvious weight gain or edema, or jaundice or hepatic 
damage. Adverse events were elicited by interview at each visit. 
All adverse events were reported by each investigator as to dura-
tion, severity, and outcome. 
Results 
Patient population 
A total of 131 patients were screened for entry into the study. 
Ofthe 113 who qualified for active therapy, 55 were randomly 
allocated to receive enteric-coated fenoprofen and 58 to receive 
fenoprofen calcium. Another patient, who qualified for active 
therapy and participated in the study, was excluded because his 
data were unavailable at the time of analysis. Distribution ofthe 
113 patients among the six investigators and two treatment 
groups was relatively well balanced. The differences between 
the two treatment groups were not statistically significant for any 
of the variables described below. 
Thirty-nine (71%) of the patients receiving enteric-coated 
fenoprofen and 45 (78%) receiving fenoprofen calcium were 
women. Forty-one (75%) patients receiving enteric-coated 
fenoprofen and 45 (78%) receiving fenoprofen calcium were 
white; 14 (25%) patients receiving enteric-coated fenoprofen 
and 13 (22%) receiving fenoprofen calcium were black. The 
knee was the involved osteoarthritic joint in 43 patients receiv-
ing enteric-coated fenoprofen and in 50 receiving fenoprofen 
calcium. The hip was involved in 12 patients receiving enteric-
coated fenoprofen and in eight receiving fenoprofen calcium. 
Age distribution of patients in the two treatment groups is 
given in Table 1. The mean age was 64 years in both groups. In 
the group receiving enteric-coated fenoprofen, 48 (87%) of 55 
were between 51 and 80 years old. In the group receiving 
fenoprofen calcium, 50 (86%) of 58 were in this age range. 
On admission to the study, 38 (69%) patients in the enteric-
coated fenoprofen group and 45 (78%) in the fenoprofen cal-
cium group listed a current sign, symptom, or illness other than 
Henry Ford Hosp Med J—Vol 36. No 1. 1988 Fenoproten in Osteoarthritis—Bluhm et al 57 
Table 1 
Age Distribution of Patients with Large-Joint 
Osteoarthritis Receiving Enteric-Coated Fenoprofen 
or Standard Fenoprofen Calcium 
Enteric-Coated Standard 
Fenoprofen (n = 55) Fenoprofen Calcium (n = 58) 
Number (%) Number (%) 
Age of Patients of Patients 
< 30 0 1 (2) 
31-40 1 (2) 0 
41-50 4 (7) 5 (9) 
51-60 16 (29) 13 (22) 
61-70 16 (29) 23 (40) 
71-80 16 (29) 14 (24) 
> 81 2 (4) 2 (3) 
osteoarthritis. Forty-one (75%) patients in the enteric-coated 
fenoprofen group and 45 (78%) in the fenoprofen calcium group 
reported concomitant drug therapy on admission, which con-
tinued throughout the study. 
During the placebo qualification period, the number of 
acetaminophen capsules taken as an analgesic was monitored 
and then recorded at the start of the treatment phase. The mean 
number of capsules taken was 31 for patients receiving enter-
ic-coated fenoprofen and 30 for patients receiving fenopro-
fen calcium. 
Analysis of efficacy variables 
For all efficacy variables, the tests for changes within each 
individual treatment group were statistically significant (P < 
0.001) for both the endpoint analysis (Table 2) and the monthly 
analysis. Thus, patients in both treatment groups experienced 
improvement in their disease condition. 
The primary analysis of efficacy was the endpoint analysis on 
all data (Table 2). No statistically significant differences were 
noted between the treatment groups for any of the efficacy mea-
sures. Also, the difference at baseline was not significant. 
For the secondary analysis of data at each of the three months, 
the only statistically significant treatment difference occurred 
during the second month for the variables of pain with weight-
bearing activity and pain on passive motion (Table 3). In both 
instances, the group receiving fenoprofen calcium showed 
greater improvement than the group receiving enteric-coated 
fenoprofen. No statistically significant differences were noted at 
the first and third months. 
Several visits were considered unevaluable for various rea-
sons such as protocol violation, use of other analgesics, or poor 
compliance. Sixteen (29%) patients receiving enteric-coated 
fenoprofen and ten (17%) receiving fenoprofen calcium had at 
least one visit declared unevaluable; however, this difference 
was not statistically significant. When ANOVA was repeated for 
the endpoint analysis on evaluable data only, the conclusions did 
not differ from those for the analysis of all data. No significant 
differences between treatment groups were observed. 
The secondary analysis for each of the three months was also 
repeated for evaluable data only. Results were similar to those 
obtained for the analysis of all data, except that differences for 
the two efficacy variables of pain with weight-bearing activity 
and pain on passive motion were no longer statistically signifi-
cant at the second month. 
Adverse events 
The overall incidence of adverse events was similar for the 
two treatment groups, with 36 (65%) of the patients receiving 
enteric-coated fenoprofen and 41 (71%) of those receiving stan-
dard fenoprofen reporting an adverse event at some time during 
the study. Events reported by two or more patients in either treat-
ment group consisted of abdominal pain, flatulence, nausea, 
dyspepsia, diarrhea (not otherwise specified), headache, vomit-
ing, constipation, upper respiratory infection, urinary tract in-
fection (not otherwise specified), nasal congestion, sinusttis, 
cough, dry mouth, peripheral edema, and potassium deficiency. 
No statistically significant differences were noted between treat-
ment groups for any of the adverse events reported during 
the study. 
Ofthe 13 (11.4%) patients who withdrew from the study be-
cause of an adverse experience, five had been receiving enteric-
coated fenoprofen and eight had been receiving fenoprofen cal-
cium (Table 4). Two patients were withdrawn from the study 
when they were hospitalized: one had a myocardial infarction, 
and the other had mild vaginal bleeding resulting from a severe 
urinary tract infection. One other patient, who was also hospi-
talized during the study for a urinary tract infection, retumed to 
Table 2 
Endpoint Analysis of All Data for Four Efficacy Variables on 113 Patients Receiving Enteric-Coated 
Fenoprofen or Standard Fenoprofen for TVeatment of Large-Joint Osteoarthritis 
Variable Treatment Number Baseline* Endpoint* Difference*t 
Tenderness on 
pressure 
Enteric-coated 
Standard 
55 
58 
2.00 ± 0.84 
2.09 ± 0.76 
0.69 ± 0.77 
0.67 ± 0.76 
1.31 ± 0.90 
1.41 ± 0.80 
Pain at rest Enteric-coated 
Standard 
55 
58 
1.51 ± 0.94 
1.64 ± 0.93 
0.62 ± 0.87 
0.47 ± 0.82 
0.89 ± 1.08 
1.17 ± 1.08 
Pain with 
weight-bearing 
Enteric-coated 
Standard 
55 
58 
2.38 ± 0.71 
2.57 ± 0.60 
1.45 ± 0.81 
1.40 ± 0.84 
0.93 ± 0.90 
1.17 ± 0.80 
activity 
Pain on passive 
motion 
Enteric-coated 
Standard 
55 
58 
2.00 ± 0.88 
2.22 ± 0.73 
0.76 ± 0.79 
0.79 ± 0.79 
1.24 ± 0.92 
1.43 ± 0.82 
*Mcan ± standard deviation. r . 
tWhen the two treatment groups were compared, the P-valuc of the differences between baseline and endpoint was not signilicant for any of the four 
variables. However, within cach treatment group the difference between baseline and endpoint was significanl (P < 0,(X)1) for all four variables. 
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Table 3 
Second-Month Analysis of All Data for Four Efficacy Variables on Patients Receiving Enteric-
Coated Fenoprofen or Standard Fenoprofen for TVeatment of Large-Joint Osteoarthritis 
Variable Treatment Number Baseline* Endpoint* Difference* P-value 
Tenderness on Enteric-coated 4,S 2,00 ± 0,85 0,71 ± 0,58 1,29 ± 0,68 0,322 
pressure Standard 52 2,08 ± 0,76 0,63 ± 0,69 1,44 ± 0,80 
Pain at rest Enteric-coated 48 1,50 ± 0,92 0,67 ± 0,75 0,83 ± 0,95 0.229 
Standard 52 1,56 ± 0,94 0,46 ± 0,70 1,10 ± 0,98 
Pain with Enteric-coated 4S 2,38 ± 0,70 1,40 ± 0,71 0,98 ± 0,86 0.040 
weight-bearing Standard 52 2,52 ± 0,61 1,25 ± 0,71 1,27 ± 0,79 
activity 
Pain on passive Enteric-coated 48 1,98 ± 0,91 0,88 ± 0,70 1,10 ± 0,86 0.046 
motion Standard 52 2,19 ± 0,74 0,73 ± 0,66 1,46 ± 0,80 
*Mean ± standard deviation. 
active study medication after she had recovered and completed 
the full course of study. No deaths occurred during the study. 
Laboratory results 
No adverse events were detected by blood chemistty (includ-
ing liver and renal function) or hematological tests during the 
study. No patients withdrew because of hematological events, 
and no adverse events were associated with WBC counts in 
any patient. 
Fifty-three (96%) of the patients receiving enteric-coated 
fenoprofen and 54 (93%) receiving standard fenoprofen had 
adequate serum samples for determination of drug concentra-
tions. The mean serum concentrations (± standard deviation) in 
the enteric-coated fenoprofen and standard fenoprofen calcium 
groups were 29.5 ± 15.6 pg/mL and 35.6 ± 19.9 pg/mL, 
respectively (P = 0.086). However, capsule counts during 
the study indicated slightly better compliance in patients receiv-
ing standard fenoprofen calcium; mean tablets per day were 
3.4 in the group receiving enteric-coated fenoprofen and 3.7 
in the group receiving standard fenoprofen (P = 0.028), 
which may largely explain the observed differences in mean 
semm concentrations. 
Table 4 
Adverse Events Resulting in Withdrawal from the Study 
in 13 Patients Receiving Enteric-Coated Fenoprofen 
or Standard Fenoprofen Calcium for Treatment 
of Large-Joint Osteoarthritis 
Patient 
Number Adverse Event 
Days on Study Drug 
Before Treatment 
Was Discontinued 
Enteric-Coated Fenoprofen 
1 Nausea 56 
2 Moderate epigastric pain 27 
3 Moderate epigastric pain, nausea 10 
4 Moderate diarrhea 29 
5 Blurred vision 52 
Standard Fenoprofen Calcium 
1 Moderate nausea, vomiting. 
severe headache 1 
2 Moderate dyspepsia 56 
3 Allergic reaction/facial edema 98 
4 Mild myocardial infarction 65 
5 Severe urinary tract infection 49 
6 Mi ld diarrhea 74 
7 Moderate diarrhea 54 
8 Cardiovascular accident 24 
Withdrawal from the study 
Patients were withdrawn from the study for the following rea-
sons; adverse event (13 patients), lack of efficacy (six patients), 
patient's decision (one patient), protocol violation (one patient), 
and lost to follow-up (one patient). The number of patients 
who completed the study included 44 (80%) from the enteric-
coated fenoprofen group and 47 (81%) from the fenoprofen cal-
cium group. 
Discussion 
This study was designed to determine whether an enteric-
coated form of fenoprofen is as effective and safe as standard 
fenoprofen. By all four measures of efficacy tested, there were 
no consistent statistically significant differences between the 
two treatment groups. With both treatments, efficacy measures 
improved from baseline to each subsequent visit. Patients who 
received enteric-coated fenoprofen experienced the same im-
provement as those who received standard fenoprofen calcium. 
This improvement was the same for both the primary analysis, 
which compared baseline and endpoint variables, and for the 
secondary analysis, which compared variables at each of the 
three months of the treatment phase. 
The only statistically significant differences occurred during 
the second month of the secondary analysis when all data were 
evaluated. At month 2, patients receiving fenoprofen calcium 
showed statistically significant greater improvement than pa-
tients receiving enteric-coated fenoprofen in the efficacy mea-
sures of pain with weight-bearing activity and pain on passive 
motion. However, this treatment difference was not significant at 
months 1 or 3. Furthermore, when the same analysis was per-
formed on evaluable data only, no statistically significant dif-
ference was evident at any of the three months. 
The adverse events encountered in this study did not have a 
statistically significant difference between the two treatment 
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groups and were of a type, severity, and incidence normally seen 
with fenoprofen and other NSAIDs (13). No deaths occurred 
during the study, and no permanently disabling adverse experi-
ences were attributable to treatment with either formulation of 
fenoprofen. Only 13 (11.4%) patients withdrew from the study 
because of adverse events, and these patients were evenly dis-
tributed between the two treatment groups (eight in the standard 
fenoprofen group versus five in the enteric-coated group). Fur-
thermore, most adverse events were minor and mild to moder-
ately severe. 
The number of patients completing the study was similar for 
the two treatment groups (80% in the enteric-coated fenoprofen 
group and 81% in the standard fenoprofen calcium group) and 
not unexpected for a three-month clinical study in outpatients. 
This double-blind, randomized, parallel study provides evi-
dence that enteric-coated fenoprofen is as effective as standard 
fenoprofen calcium for the treatment of large-joint osteoarthritis 
with a similar safety profile. Since enteric-coated fenoprofen 
reduces the risk of Gl microbleeding (12), it may offer an 
additional safety factor for patients who require long-term 
administration of NSAIDs for large-joint osteoarthritis. 
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